Compare MPLX LP (MPLX) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs 10X Genomics Inc — how do they compare? MPLX LP trades at $56.68 (market cap $58.11B), while 10X Genomics Inc trades at $81.4 (market cap $10.07B). The key difference: MPLX LP is far larger — about 5.8× 10X Genomics Inc's market cap, and MPLX LP pays a 7.51% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| MPLX | TXG | |
|---|---|---|
Market Cap | $58.11B | $10.07B |
Volume | 687,483 | 5,657,286 |
Sector | Energy | Health |
52-Week High | $60.51 | $97.74 |
52-Week Low | $47.80 | $11.48 |
Enterprise Value | $83.22B | $9.59B |
Dividend Yield | 7.51% | — |
Typical Hold Time | — | 92 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPLX trades at $56.86, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with $11.47B revenue and 40.45% net margin, though recent earnings missed expectations. Analyst consensus remains bullish with a $63.80 price target, supported by stable cash flow and dividend payments. Technical indicators show mixed signals with RSI neutral but ADX suggesting selling pressure.
MPLX offers value with a 12.33 P/E ratio and strong profitability metrics, but faces headwinds from recent earnings misses and energy market volatility. The stock presents income appeal with dividend coverage, though investors should monitor execution on future earnings and energy price sensitivity.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
